NO20051023L - Oral administrering av calcitonin - Google Patents

Oral administrering av calcitonin

Info

Publication number
NO20051023L
NO20051023L NO20051023A NO20051023A NO20051023L NO 20051023 L NO20051023 L NO 20051023L NO 20051023 A NO20051023 A NO 20051023A NO 20051023 A NO20051023 A NO 20051023A NO 20051023 L NO20051023 L NO 20051023L
Authority
NO
Norway
Prior art keywords
calcitonin
oral administration
oral
amount
disclosed
Prior art date
Application number
NO20051023A
Other languages
English (en)
Inventor
Moise Azria
Simon David Bateman
James F Mcleod
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20051023L publication Critical patent/NO20051023L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det beskrives en metode for oral administrering av farmasøytiske preparater omfattende kalsitonin i kombinasjon med orale avleveringsmidler før forbruk av næring hos mennesker. Denne orale administrering muliggjør en metode for behandling av lidelser som er responsive på virkningen av kalsitonin. Det beskrives videre farmasøytiske, orale kalsitoninpreparater med spesielle forhold mellom mengden oralt avleveringsmiddel og mengden kalsitonin.
NO20051023A 2002-08-01 2005-02-25 Oral administrering av calcitonin NO20051023L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40013902P 2002-08-01 2002-08-01
PCT/EP2003/008498 WO2004012772A1 (en) 2002-08-01 2003-07-31 Oral administration of calcitonin

Publications (1)

Publication Number Publication Date
NO20051023L true NO20051023L (no) 2005-04-27

Family

ID=31495795

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051023A NO20051023L (no) 2002-08-01 2005-02-25 Oral administrering av calcitonin

Country Status (19)

Country Link
US (2) US20060135402A1 (no)
EP (1) EP1526871A1 (no)
JP (4) JP2005535689A (no)
KR (6) KR20170097232A (no)
CN (1) CN1671418A (no)
AR (1) AR040737A1 (no)
AU (1) AU2003260346B2 (no)
BR (1) BR0313177A (no)
CA (1) CA2494212A1 (no)
IL (1) IL166337A (no)
MX (1) MXPA05001266A (no)
NO (1) NO20051023L (no)
NZ (1) NZ537944A (no)
PE (1) PE20040724A1 (no)
PL (1) PL373143A1 (no)
RU (1) RU2355417C2 (no)
TW (1) TWI307279B (no)
WO (1) WO2004012772A1 (no)
ZA (1) ZA200500516B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006292337B8 (en) 2005-09-19 2013-02-07 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
ES2365648T3 (es) * 2007-03-02 2011-10-07 Novartis Ag Administración oral de una calcitonina.
WO2009019307A2 (en) * 2007-08-09 2009-02-12 Novartis Ag Oral calcitonin compositions and applications thereof
WO2009059188A1 (en) 2007-11-02 2009-05-07 Emisphere Technologies, Inc. Method of treating vitamin b12 deficiency
US20110039930A1 (en) * 2009-08-03 2011-02-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
CN104095828A (zh) * 2014-07-29 2014-10-15 中国药科大学 一种降钙素口服肠溶组合物及其制备方法
JP6925969B2 (ja) * 2015-02-09 2021-08-25 エンテラ バイオ エルティーディー． 医薬組成物
CN104961687B (zh) * 2015-06-03 2017-07-25 苏州维泰生物技术有限公司 1,2‑二嗪衍生物及其制剂、用途
IL321113A (en) 2016-08-17 2025-07-01 Entera Bio Ltd Formulations for oral administration of active agents
CR20230308A (es) 2020-12-11 2023-09-08 Civi Biopharma Inc Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
CR20230471A (es) 2021-04-22 2023-11-01 Civi Biopharma Inc Administración oral de oligonucleótidos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
NZ534409A (en) * 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
WO2000059480A1 (en) * 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Lyophilized solid dosage forms and methods of making
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Also Published As

Publication number Publication date
RU2355417C2 (ru) 2009-05-20
AR040737A1 (es) 2005-04-20
KR20160113319A (ko) 2016-09-28
US7569539B2 (en) 2009-08-04
KR20140084354A (ko) 2014-07-04
TW200408409A (en) 2004-06-01
IL166337A (en) 2011-10-31
AU2003260346A1 (en) 2004-02-23
AU2003260346B2 (en) 2007-12-13
US20060135402A1 (en) 2006-06-22
WO2004012772A1 (en) 2004-02-12
US20070232524A1 (en) 2007-10-04
CN1671418A (zh) 2005-09-21
MXPA05001266A (es) 2005-04-28
PE20040724A1 (es) 2004-12-06
KR20050032101A (ko) 2005-04-06
TWI307279B (en) 2009-03-11
EP1526871A1 (en) 2005-05-04
PL373143A1 (en) 2005-08-22
JP2016056190A (ja) 2016-04-21
IL166337A0 (en) 2006-01-16
BR0313177A (pt) 2005-06-14
ZA200500516B (en) 2006-07-26
KR20170097232A (ko) 2017-08-25
RU2005105691A (ru) 2006-01-20
JP2011026348A (ja) 2011-02-10
KR20130004389A (ko) 2013-01-09
CA2494212A1 (en) 2004-02-12
KR20110014690A (ko) 2011-02-11
JP5941035B2 (ja) 2016-06-29
NZ537944A (en) 2006-11-30
JP2005535689A (ja) 2005-11-24
JP2014062112A (ja) 2014-04-10

Similar Documents

Publication Publication Date Title
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BR0109875A (pt) Tratamento de doenças respiratórias
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
SE0001899D0 (sv) New compounds
NO20051023L (no) Oral administrering av calcitonin
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
AU2003301190A1 (en) Administration of capsaicinoids
TN2009000137A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
BR0207930A (pt) Composições farmacêuticas lìquidas com sabor mascarado
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
TW200607799A (en) Therapeutic compounds: pyridine as scaffold
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
DK1091733T3 (da) (-)-Pseudoephedrin som et sympatomimetisk lægemiddel
DK1497292T3 (da) Azaindolylpiperidinderivater som antihistamin- og antiallergimidler
BR0010255A (pt) Formulação farmacêutica, kit de partes, método para tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da trombina e/ou inibição da carboxipeptidase u são requeridas ou desejadas, e, uso de uma formulação
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
BR0316123A (pt) Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico
WO2004073627A3 (en) Novel therapeutic method and compositions for topical administration
IT1320772B1 (it) Composizione farmaceutica a base di agenti attivi contro la candidaper il trattamento di disturbi della mucosa orale e intestinale
DE60312215D1 (de) Pharmazeutische zusammensetzung enthaltend einen ltb4-hemmer sowie einen cox-2-hemmer oder einen kombinierten cox1/2-hemmer